权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Research on Strategy to integrate Intellectual Property Management with Product Development Process

知识产权管理与产品开发过程整合策略研究

基本信息

批准号：
16530244
负责人：
NAGATA Akiya
金额：
$ 2.05万
依托单位：
KYUSHU UNIVERSITY
依托单位国家：
日本
项目类别：
Grant-in-Aid for Scientific Research (C)
财政年份：
2004
资助国家：
日本
起止时间：
2004 至 2005
项目状态：
已结题

项目摘要

This research aimed to make a corporate strategic framework to integrate the intellectual property management with the product development processes, and to clarify the organizational structure of intellectual property division will be suitable to accomplish the integration strategy. We paid attention to the life cycle management of intellectual property in the pharmaceutical firms as a remarkable case which aiming at such integration strategy.We conducted a questionnaire survey targeting 191 Japanese pharmaceutical firms, and acquired the responses from 64 firms in 2004. The following point became clear by our analysis based on these sample data. It becomes the important subject of big pharmaceutical firms that to appropriate the profit from their own innovation, because a large sum of R&D expenditure should be necessary for the new product development. Therefore, most of the big firms have already strengthened engaging to life cycle management of the intellectual property. The engaging actually exerts effect on extension of product life cycle and the exclusion of the generic products. And, strengthening of cross-functional relationship is being attempted in the process by the establishment of the formal project team and so on.While the appropriability of the profit from innovation is raised for the innovative firms, it has the possibility that an innovation is delayed in the industry as a whole, because the strategy obstructs the diffusion of the new technology. To verify this point, we analyzed the possibility of the existence of "patent thicket" by using the data of the Japan Patent Office "Survey of Intellectual Property-Related Activities". It was shown that the possibility of patent thickets clear gradually during the past three years though it is not still observed as a serious hampering factor for innovation.

本研究旨在构建一个整合知识产权管理与产品开发过程的企业战略框架，并明确知识产权部门的组织结构将适合于整合战略的实施。我们将医药企业知识产权生命周期管理作为针对这种整合战略的典型案例加以关注。2004年，我们对191家日本制药企业进行了问卷调查，获得了64家企业的反馈。通过对这些样本数据的分析，我们清楚了以下几点。由于新产品的开发需要大量的研发经费，如何合理分配自主创新的利润成为大型制药企业的重要课题。因此，大多数大公司已经加强了对知识产权生命周期管理的投入。参与实际上对产品生命周期的延长和仿制产品的排斥具有一定的作用。在此过程中，通过组建正式的项目团队等方式尝试加强跨职能关系。虽然提高了创新企业创新利润的可占用性，但由于该策略阻碍了新技术的扩散，在整个行业中存在创新延迟的可能性。为了验证这一点，我们利用日本专利局“知识产权相关活动调查”的数据分析了“专利丛林”存在的可能性。研究表明，尽管专利壁垒仍未被视为严重阻碍创新的因素，但在过去三年中，专利壁垒的可能性逐渐消除。